What is the 13F Pro Quality Score for OABI?

13F Pro ranks OmniAb, Inc. (OABI) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View OABI's current score at https://13fpro.ai/research/OABI (free sign-up required for the full ranking).

Where does 13F Pro source OABI data?

All OmniAb, Inc. fundamentals and ownership data come directly from SEC EDGAR. OmniAb, Inc. files with the SEC under CIK 1846253. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is OABI in?

OmniAb, Inc. (OABI) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is OABI research updated on 13F Pro?

OABI's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

OmniAb, Inc.(OABI)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1846253 OABI stock profile & AI dashboard →

13F Pro Quality Score

9.7/100

Rank #2,815 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

9.6/100

Profitability

5.1/100

Balance Sheet

11.9/100

Earnings Quality

30.0/100

Free Cash Flow

5.6/100

Institutional Flow

29.8/100

Revenue Scale

6.1/100

Dilution Risk

3.4/100

OABI Stock Analysis & AI Quality Score

AI stock analysis and institutional research for OmniAb, Inc. (OABI), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores OABI at 9.7/100 on a 32-signal composite quality model, placing it at rank #2,815 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include profitability (5.1) and free cash flow (5.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), OmniAb, Inc. reports quarterly revenue of $14.4M, net income of $-7.7M, free cash flow of $-5.1M. Top institutional holders of OABI by reported 13-F value include Whitefort Capital Management,, BlackRock,, CADIAN CAPITAL MANAGEMENT,, based on the most recent SEC filings. OABI trades on the Nasdaq exchange and files with the SEC under CIK 1846253. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OABI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for OmniAb, Inc. directly from SEC EDGAR. OmniAb, Inc.'s 13F Pro composite quality score has ranged between 5 and 43 since 2023, currently 9.7 — a declining long-term trajectory across 48 quarterly and live scoring snapshots.

✦

Fun facts about OmniAb, Inc.

Quirks, history, and lore behind OABI — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biotechnology company · small-cap · listed on Nasdaq · headquartered in California.
2
The Numbers
A pre-profitability biotech with annual revenue in the tens of millions, funded largely by partnerships and licensing deals with larger pharmaceutical companies.
3
The History
The company went public via a SPAC merger in late 2022, spinning out of Ligand Pharmaceuticals to stand on its own as a dedicated antibody-discovery platform.
4
The Secret
Its core trick is engineering transgenic animals — including chickens — whose immune systems churn out fully human antibodies that drug companies can turn into therapeutics.
5
The Lore
Using chickens as antibody factories sounds like a science-fair project, but the approach unlocks targets that mice and rats simply can't reach — giving partners a meaningful edge in drug discovery.
6
The Giveaway
Its name literally means "all antibodies" — an Omni-vorous platform for generating Abodies from transgenic animals, spun out of Ligand and traded under a ticker that matches its name letter for letter.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$14.4M

Net Income

Q1 2026

$-7.7M

Free Cash Flow

Q1 2026

$-5.1M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-22.8% YoY

$26.4MFY 2024

FY20 —FY22 $59.1MFY23 $34.2MFY24 $26.4M

Net Income

-22.5% YoY

$-62.0MFY 2024

FY20 —FY22 $-22.3MFY23 $-50.6MFY24 $-62.0M

Operating Income

-7.3% YoY

$-74.5MFY 2024

FY20 —FY22 $-26.6MFY23 $-69.4MFY24 $-74.5M

EPS (Diluted)

-19.6% YoY

$-0.61FY 2024

FY20 —FY22 $-0.26FY23 $-0.51FY24 $-0.61

Total Assets

-13.2% YoY

$325.6MFY 2024

FY20 —FY22 $421.2MFY23 $375.2MFY24 $325.6M

Op. Cash Flow

-1790.0% YoY

$-39.7MFY 2024

FY20 —FY22 $-3.6MFY23 $2.3MFY24 $-39.7M

Metric	FY 2024	FY 2023	FY 2022	FY 2020
Revenue	$26.4M -22.8%	$34.2M -42.2%	$59.1M	—
Net Income	$-62.0M -22.5%	$-50.6M -126.6%	$-22.3M	—
Operating Income	$-74.5M -7.3%	$-69.4M -160.5%	$-26.6M	—
EPS (Diluted)	$-0.61 -19.6%	$-0.51 -96.2%	$-0.26	—
Total Assets	$325.6M -13.2%	$375.2M -10.9%	$421.2M	—
Operating Cash Flow	$-39.7M -1790.0%	$2.3M +165.4%	$-3.6M	—

AI Insight: OABI Financial Trends

OmniAb's revenue surged to $14M in Q1 2026, while operating losses narrowed to $8M from $18M year-over-year.

• Revenue jumped from $4M in Q1 2025 to $14M in Q1 2026, marking the highest quarterly revenue in the dataset.

• Operating losses improved dramatically from $19M in Q1 2025 to $8M in Q1 2026.

• Operating cash flow has remained consistently negative, ranging from $4M to $16M outflow across all quarters.

⚠ Equity declined from $294M in Q2 2024 to $263M in Q1 2026 despite no debt on balance sheet.

⚠ Revenue volatility remains high, swinging from $2M in Q3 2025 to $14M in Q1 2026.

AI Insight: OABI Ratio Trends

OABI showed dramatic improvement in Q1 2026 with operating margin rising to -54.3% from -188.2% in Q4 2025.

• Operating margin improved substantially from -188.2% in Q4 2025 to -54.3% in Q1 2026.

• Net profit margin recovered to -53.4% in Q1 2026 from -169.3% in Q4 2025.

• ROE improved from -21.2% in Q4 2025 to -11.7% in Q1 2026.

• ROIC strengthened from -23.6% in Q4 2025 to -11.9% in Q1 2026.

⚠ All profitability metrics remain deeply negative despite recent improvements.

⚠ Need to monitor if Q1 2026 improvement represents sustainable trend or one-time benefit.

Get alerted when OABI's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for OmniAb, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of OABI

Whitefort Capital Management, LP
$22.3M14,223,658 sh
BlackRock, Inc.
$12.7M8,106,881 sh
CADIAN CAPITAL MANAGEMENT, LP
$6.5M4,157,129 sh
VANGUARD CAPITAL MANAGEMENT LLC
$6.3M3,993,652 sh
GEODE CAPITAL MANAGEMENT, LLC
$4.6M2,925,579 sh
RICE HALL JAMES & ASSOCIATES, LLC
$4.0M2,547,255 sh
PRIVATE MANAGEMENT GROUP INC
$3.8M2,429,166 sh
STATE STREET CORP
$3.2M2,067,143 sh
DIMENSIONAL FUND ADVISORS LP
$2.7M1,745,248 sh
TOWERVIEW LLC
$1.6M1,000,000 sh

Fund	Value	Shares
Whitefort Capital Management, LP	$22.3M	14,223,658
BlackRock, Inc.	$12.7M	8,106,881
CADIAN CAPITAL MANAGEMENT, LP	$6.5M	4,157,129
VANGUARD CAPITAL MANAGEMENT LLC	$6.3M	3,993,652
GEODE CAPITAL MANAGEMENT, LLC	$4.6M	2,925,579
RICE HALL JAMES & ASSOCIATES, LLC	$4.0M	2,547,255
PRIVATE MANAGEMENT GROUP INC	$3.8M	2,429,166
STATE STREET CORP	$3.2M	2,067,143
DIMENSIONAL FUND ADVISORS LP	$2.7M	1,745,248
TOWERVIEW LLC	$1.6M	1,000,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put OABI on your watchlist

Track score changes the day OmniAb, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is OABI a good stock to buy?

13F Pro's AI-powered analysis of OmniAb, Inc. (OABI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for OABI are available on the OABI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own OABI?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling OABI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of OmniAb, Inc.'s investment landscape.